Wall Street brokerages forecast that Loxo Oncology, Inc. (NASDAQ:LOXO) will post earnings per share of ($0.99) for the current quarter, according to Zacks. Zero analysts have made estimates for Loxo Oncology’s earnings. The highest EPS estimate is ($0.89) and the lowest is ($1.05). Loxo Oncology posted earnings per share of ($0.77) in the same quarter last year, which suggests a negative year-over-year growth rate of 28.6%. The company is scheduled to announce its next quarterly earnings results on Tuesday, August 8th.

On average, analysts expect that Loxo Oncology will report full-year earnings of ($4.17) per share for the current fiscal year, with EPS estimates ranging from ($4.51) to ($3.59). For the next financial year, analysts expect that the firm will report earnings of ($3.92) per share, with EPS estimates ranging from ($4.67) to ($2.83). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Loxo Oncology.

Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by $0.16. During the same period last year, the company earned ($0.77) EPS.

A number of research analysts recently commented on LOXO shares. BTIG Research reaffirmed a “buy” rating and issued a $75.00 price target on shares of Loxo Oncology in a research note on Tuesday, June 6th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $71.00 price target on shares of Loxo Oncology in a research note on Thursday, August 3rd. Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $52.00 price target for the company in a research note on Wednesday, May 3rd. Citigroup Inc. raised Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 price target for the company in a research note on Monday, June 5th. Finally, BidaskClub downgraded Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $75.83.

In other Loxo Oncology news, Director Keith T. Flaherty sold 7,250 shares of the business’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $45.09, for a total transaction of $326,902.50. Following the completion of the transaction, the director now owns 27,141 shares of the company’s stock, valued at $1,223,787.69. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 27.80% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of LOXO. Legal & General Group Plc increased its position in shares of Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 284 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 905 shares during the last quarter. Alps Advisors Inc. increased its position in shares of Loxo Oncology by 7.4% in the second quarter. Alps Advisors Inc. now owns 23,601 shares of the biopharmaceutical company’s stock valued at $1,893,000 after buying an additional 1,623 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Loxo Oncology by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 44,178 shares of the biopharmaceutical company’s stock valued at $1,860,000 after buying an additional 2,045 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Loxo Oncology by 27.1% in the first quarter. American International Group Inc. now owns 9,749 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 2,081 shares during the last quarter.

WARNING: This report was reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/09/brokerages-expect-loxo-oncology-inc-nasdaqloxo-to-announce-0-99-eps.html.

Shares of Loxo Oncology (NASDAQ LOXO) opened at 73.11 on Wednesday. Loxo Oncology has a 12-month low of $17.14 and a 12-month high of $83.12. The stock has a 50 day moving average of $75.35 and a 200 day moving average of $53.58. The company’s market cap is $1.91 billion.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Get a free copy of the Zacks research report on Loxo Oncology (LOXO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.